-+ 0.00%
-+ 0.00%
-+ 0.00%

Cardiol CEO Elsley discusses MAVERIC Phase III trial in live X interview with Barchart

PUBT·04/14/2026 11:30:41
Listen to the news
Cardiol CEO Elsley discusses MAVERIC Phase III trial in live X interview with Barchart
  • Cardiol Therapeutics CEO David Elsley held a live interview on X hosted by Barchart at 12:00 p.m. EDT.
  • Management highlighted ongoing pivotal Phase III MAVERIC trial of CardiolRx in recurrent pericarditis.
  • Discussion covered recently published Phase II ARCHER results for CardiolRx in acute myocarditis.
  • Interview also outlined development plans for next-generation candidate CRD-38 for heart failure.
  • Recording slated for posting on Cardiol’s X channel and Barchart’s account.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiol Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001062993-26-001963), on April 14, 2026, and is solely responsible for the information contained therein.